ANNOUNCEMENT

Take a look at the MedCity ENGAGE program, with expert speakers from leading organizations. Reserve your place today.

Topic: Icagen

PFE gives ICGN shareholders last chance to accept $56M deal

PFE gives ICGN shareholders last chance to accept $56M deal

September 13, 2011 10:44 am by | 0 Comments

Nearly one-third of Icagen (NASDAQ:ICGN) shareholders have yet to accept Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company and the pharmaceutical giant is giving them one last ... Read more
Pfizer secures enough shares for Icagen acquisition

Pfizer secures enough shares for Icagen acquisition

September 6, 2011 11:04 am by | 0 Comments

Pfizer‘s (NYSE:PFE) Icagen (NASDAQ:ICGN) acquisition is a go.After two extensions last week, Pfizer announced today that it has enough shares tendered for sale for the $56 million cash deal to ... Read more
Pfizer’s Icagen offer extended again; now expires at 6 p.m.

Pfizer’s Icagen offer extended again; now expires at 6 p.m.

September 2, 2011 9:57 am by | 0 Comments

Icagen‘s (NASDAQ:ICGN) sale to Pfizer (NYSE:PFE) hangs in the balance by 39,799 shares.That’s the minimum number of shares that need to be tendered for the $56 million sale to proceed. ... Read more
Pfizer extends Icagen offer; remains just shy of shares needed for deal

Pfizer extends Icagen offer; remains just shy of shares needed for deal

September 1, 2011 10:26 am by | 0 Comments

Pfizer‘s (NYSE:PFE) $56 million offer for Icagen (NASDAQ:ICGN) has been extended one more day as the pharmaceutical giant remains just shy of the minimum shares needed to execute the acquisition.Unless ... Read more
PFE to ICGN shareholders: ‘$6 per share is our best and final price’

PFE to ICGN shareholders: ‘$6 per share is our best and final price’

August 26, 2011 4:56 pm by | 0 Comments

Pfizer (NYSE:PFE) will not raise its offer to acquire Icagen (NASDAQ:ICGN).The pharmaceutical giant sent a letter to Icagen’s board of directors today holding firm on its purchase price of $6 ... Read more
Investors blocking PFE’s $56M ICGN bid say firm’s value could be $165M

Investors blocking PFE’s $56M ICGN bid say firm’s value could be $165M

August 12, 2011 3:45 pm by | 0 Comments

Two Icagen (NASDAQ:ICGN) institutional investors opposed to Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company now say the company’s value should be nearly three times that amount.Merlin ... Read more
Icagen executive Suto departs for Southern Research Institute post

Icagen executive Suto departs for Southern Research Institute post

August 12, 2011 11:16 am by | 0 Comments

Pfizer‘s (NYSE:PFE) Icagen (NASDAQ:ICGN) acquisition has yet to close, but the talent exodus from the drug development company is already under way.Mark Suto, Icagen’s vice president of chemical and pharmaceutical ... Read more
Pfizer-Icagen deal: PFE’s $56M cash offer for ICGN beat two other bids

Pfizer-Icagen deal: PFE’s $56M cash offer for ICGN beat two other bids

August 10, 2011 1:38 pm by | 1 Comments

Pfizer‘s (NYSE:PFE) $56 million offer to acquire Icagen (NASDAQ:ICGN) followed a mostly fruitless courtship dating back five years that ultimately saw the pharma giant beat out two others who vied ... Read more
Pfizer-Icagen deal faces problem: Merlin Nexus opposes price

Pfizer-Icagen deal faces problem: Merlin Nexus opposes price

July 29, 2011 1:03 pm by | 0 Comments

Pfizer’s (NYSE:PFE) $56 million bid to acquire Icagen (NASDAQ:ICGN) faces a big hurdle – two of Icagen’s largest shareholders.Merlin Nexus and New Leaf Venture Partners, two firms holding Icagen stock, ... Read more
Pfizer acquires Icagen for $56 million

Pfizer acquires Icagen for $56 million

July 20, 2011 10:18 am by | 0 Comments

Pfizer (NYSE:PFE) will acquire North Carolina drug development company Icagen (NASDAQ:ICGN) for $56 million in a move to bolster its own pain drug pipeline.Under terms of the agreement, Pfizer, which ... Read more
Pfizer-Icagen merger: What ICGN could bring to PFE’s portfolio

Pfizer-Icagen merger: What ICGN could bring to PFE’s portfolio

June 28, 2011 2:07 pm by | 0 Comments

Pfizer (NYSE:PFE) is now talking about a possible acquisition of Icagen (NASDAQ:ICGN). But, already, Pfizer is Icagen’s primary supporter.Icagen, which is based in Durham, North Carolina, has relied on a ... Read more
Could NC biotech Icagen get acquired by Pfizer?

Could NC biotech Icagen get acquired by Pfizer?

June 27, 2011 10:27 am by | 2 Comments

Pfizer (NYSE:PFE) is taking a hard look at acquiring the NC biotech company Icagen (NASDAQ:ICGN) in a move that could bring a slate of pain drug candidates into the pipeline ... Read more
N.C. pharma Icagen names Krafte chief scientific officer

N.C. pharma Icagen names Krafte chief scientific officer

April 26, 2011 12:43 pm by | 0 Comments

North Carolina biopharmaceutical company Icagen (NASDAQ:ICGN) has promoted executive Douglas Krafte to the newly created position of chief scientific officer.Krafte has been vice president of biology and scientific affairs at ... Read more
Pfizer milestone payment for pain treatment lifts Icagen revenue

Pfizer milestone payment for pain treatment lifts Icagen revenue

March 7, 2011 3:33 pm by | 0 Comments

New pain drugs being developed in partnership with Pfizer hit key goals, triggering milestone payments to North Carolina drug development company Icagen. The partners are moving forward with their drug ... Read more
Icagen’s epilepsy drug study gets FDA OK to resume

Icagen’s epilepsy drug study gets FDA OK to resume

February 2, 2011 11:39 am by | 0 Comments

Biopharmaceutical company Icagen can resume clinical studies on its epilepsy drug candidate after the U.S. Food and Drug Administration removed a hold it had placed on the compound last fall ... Read more